Phase 1 Trial starts for Achillion’s Oral Therapy
Posted on
“Achillion Pharmaceuticals, Inc. announced (10 July) that the Company had begun dosing healthy volunteer subjects in a first-in-human phase 1 trial of ACH-5548, an oral small-molecule complement factor D inhibitor. ACH-5548 is the third clinical compound discovered and developed by Achillion from its complement factor D platform.”
Please read more here.